原位杂交市场规模 - 按产品（消耗品、仪器、服务）、技术（萤光原位杂交、显色原位杂交）、应用（癌症、细胞遗传学、免疫学）、最终用途和预测 2024 - 2032

由于分子生物学的进步以及个人化医疗需求的增加，2024年至2032年全球原位杂交市场规模将以8.6%的复合年增长率扩大。这些创新实现了精确的遗传和分子分析，这对于个人化治疗策略至关重要。随着医疗保健转向基于个别基因图谱的客製化疗法，对原位杂交等准确诊断工具的需求日益增长。这一趋势推动了持续的研究和开发，提高了原位杂交测定的敏感度和特异性，从而扩大了其在肿瘤学、传染病和遗传性疾病领域的应用。

例如，2023 年 12 月，Cytelabs 推出了乳癌 DISH 检测，这是与 Cytecare 癌症医院合作推出的一项专门的肿瘤病理学诊断服务。它越来越多地用于确定乳癌患者的 HER2 状态，标誌着癌症诊断的重大进步。它凸显了个人化医疗和精准肿瘤学的趋势，透过提高乳癌和其他可能的肿瘤疾病的诊断准确性和治疗效果来影响市场动态。

原位杂交产业根据产品、技术、应用、最终用途和地区进行划分。

由于其简单性、成本效益以及在癌症诊断和分子病理学中的广泛适用性，显色原位杂交部分将在 2032 年之前建立一个值得注意的立足点。该方法能够以高灵敏度和特异性可视化基因表现模式，这使其在临床和研究环境中至关重要。随着对精确疾病诊断和个人化医疗的需求不断增长，显色原位杂交技术将保持其主导地位，以满足全球日益增长的医疗保健需求。

受其在研究胚胎发育和组织分化过程中基因表现模式的关键作用的推动，到 2032 年，发育生物学领域将经历相当大的改善。此技术能够精确定位细胞和组织内的 mRNA 和 DNA 序列，支持发育过程和器官发生的研究。随着发育生物学科学进步的加速，对原位杂交技术来阐明复杂生物机制的需求将会成长，从而巩固了该领域在分子生物学研究中的重要地位。

在医疗保健支出增加、慢性病发病率上升和生物技术研究扩大的推动下，亚太地区原位杂交市场份额将在 2024 年至 2032 年间实现显着的复合年增长率。中国、印度和日本等国家发挥关键作用，推动了对先进诊断技术的需求。政府措施和医疗基础设施投资等因素进一步促进了该地区的市场成长。这些动态使亚太地区成为原位杂交产业的主要贡献者，促进了分子诊断领域的创新和技术进步。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 目标疾病盛行率增加
    • 体外诊断领域的技术进步
    • 体外诊断研发投资不断增加
  • 产业陷阱与挑战
    • 原位杂交成本高
    • 监理框架不明确
• 成长潜力分析
• 技术景观
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

• 主要趋势
• 耗材
  • 探头
  • 试剂盒和试剂
  • 配件
• 仪器
• 服务

第 6 章：市场估计与预测：按技术分类，2021 - 2032 年

• 主要趋势
• 萤光原位杂交
  • DNA萤光原位杂交
  • RNA萤光原位杂交
  • PNA萤光原位杂交
• 显色原位杂交

第 7 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 癌症
• 细胞遗传学
• 发育生物学
• 传染性疾病
• 神经科学
• 免疫学
• 其他应用

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 医院和诊断实验室
• 学术及研究机构
• 合约研究组织
• 製药和生物技术公司
• 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Agilent Technologies, Inc.
• Bio-Techne Corporation
• Bio-Rad Laboratories, Inc.
• Bio View Ltd.
• Danaher Corporation
• Merck KGaA
• Neogenomics, inc.
• PerkinElmer, Inc.
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

Global In-situ Hybridization Market size will expand at an 8.6% CAGR from 2024 to 2032, attributed to advancements in molecular biology coupled with increasing demand for personalized medicine. These innovations enable precise genetic and molecular profiling, which is crucial for personalized treatment strategies. As healthcare shifts towards tailored therapies based on individual genetic profiles, there is a growing need for accurate diagnostic tools like in-situ hybridization. This trend drives ongoing research and development, enhancing the sensitivity and specificity of in-situ hybridization assays and thus expanding their applications across oncology, infectious diseases, and genetic disorders.

For instance, in December 2023, Cytelabs introduced DISH testing for breast cancer, a specialized oncopathology diagnostic service launched in collaboration with Cytecare Cancer Hospital. It is increasingly used to determine HER2 status in breast cancer patients, marking a substantial advancement in cancer diagnostics. It highlights a trend towards personalized medicine and precision oncology, influencing market dynamics by enhancing diagnostic accuracy and treatment efficacy for breast cancer and possibly other oncological conditions.

The in-situ hybridization industry is divided based on product, technology, application, end-use, and region.

The chromogenic in-situ hybridization segment will establish a noteworthy foothold through 2032, owing to its simplicity, cost-effectiveness, and wide applicability in cancer diagnostics and molecular pathology. This method's ability to visualize gene expression patterns with high sensitivity and specificity makes it essential in clinical and research settings. As demand grows for precise disease diagnosis and personalized medicine, the chromogenic in-situ hybridization technique will maintain its dominance, catering to increasing healthcare needs globally.

The developmental biology segment will experience a considerable upturn by 2032, propelled by its critical role in studying gene expression patterns during embryonic development and tissue differentiation. This technique enables precise localization of mRNA and DNA sequences within cells and tissues, supporting research in developmental processes and organogenesis. As scientific advancements in developmental biology accelerate, the demand for in-situ hybridization techniques to elucidate complex biological mechanisms will grow, solidifying the segment's significant position in molecular biology research.

Asia Pacific in-situ hybridization market share will record a remarkable CAGR between 2024 and 2032, fueled by increasing healthcare expenditure, rising incidence of chronic diseases, and expanding biotechnology research. Countries like China, India, and Japan are pivotal, driving demand for advanced diagnostic techniques. Factors such as government initiatives and investments in healthcare infrastructure further bolster market growth in the region. These dynamics position Asia Pacific as a primary contributor to the in-situ hybridization industry, fostering innovation and technological advancements in molecular diagnostics.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of target disorders
    • 3.2.1.2 Technological advancement in the field of in-vitro diagnostics
    • 3.2.1.3 Rising R&D investments in in-vitro diagnostics
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of in-situ hybridization
    • 3.2.2.2 Presence of an ambiguous regulatory framework
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Consumables
  • 5.2.1 Probes
  • 5.2.2 Kits and reagents
  • 5.2.3 Accessories
• 5.3 Instruments
• 5.4 Services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Fluorescent in-situ hybridization
  • 6.2.1 DNA fluorescent in-situ hybridization
  • 6.2.2 RNA fluorescent in-situ hybridization
  • 6.2.3 PNA fluorescent in-situ hybridization
• 6.3 Chromogenic in-situ hybridization

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Cancer
• 7.3 Cytogenetics
• 7.4 Developmental biology
• 7.5 Infectious diseases
• 7.6 Neuro science
• 7.7 Immunology
• 7.8 Other applications

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and diagnostic laboratories
• 8.3 Academic and research institutes
• 8.4 Contract research organizations
• 8.5 Pharmaceuticals and biotechnology companies
• 8.6 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Agilent Technologies, Inc.
• 10.2 Bio-Techne Corporation
• 10.3 Bio-Rad Laboratories, Inc.
• 10.4 Bio View Ltd.
• 10.5 Danaher Corporation
• 10.6 Merck KGaA
• 10.7 Neogenomics, inc.
• 10.8 PerkinElmer, Inc.
• 10.9 Sysmex Corporation
• 10.10 Thermo Fisher Scientific Inc.